版本:
中国

BRIEF-Tonix Pharmaceuticals to commence "honor" study this quarter

March 7 Tonix Pharmaceuticals Holding Corp

* Tonix Pharmaceuticals Holding says will commence in this quarter "honor" study, a 12-week phase 3 clinical study evaluating TNX-102 SL, 5.6 mg, in military-related PTSD

* Tonix Pharmaceuticals Holding says interim analysis of honor study is expected in first half of 2018, topline results are expected in second half of 2018 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐